β2-integrins as biomarkers in urothelial cancer
Marc Llort Asens, Imran Khan, Susanna Carola Fagerholm, Xing-Xiong An, Xing-Xiong An, Xing-Xiong An
TL;DR
This study explores β2-integrins as potential biomarkers in urothelial cancer, linking their expression to immune cell infiltration and patient outcomes.
Contribution
The study identifies specific β2-integrins and their regulators associated with survival and immune response in urothelial cancer.
Findings
ITGAL and FERMT3 correlate with improved patient survival and increased CD8+ T cell and NK cell infiltration.
ITGAM, ITGAX, and FLNA are linked to poor survival and reduced immunotherapy response, affecting myeloid cell populations.
β2-integrins may serve as biomarkers to distinguish immune landscapes and treatment responses in urothelial cancer.
Abstract
β2-integrins are a family of adhesion proteins expressed in immune cells that play multiple roles in anti-tumor immunity. β2-integrins regulate tumor infiltration of anti-tumorigenic immune cells such as cytotoxic CD8 + T cells and NK cells. However, they also regulate the activity of myeloid cells, such as macrophages, which can have both anti- and pro-tumorigenic properties. The role of β2-integrins in urothelial cancer remains poorly understood. Here, we have investigated the role of different β2-integrins, and their cytoplasmic regulators, in urothelial cancer, by utilizing RNA expression data. We found that ITGAL (encoding for CD11a) and FERMT3 (encoding for the integrin regulator kindlin-3) have a positive correlation with patient survival. EcoTyper analysis revealed increased infiltration of CD8 + T cells and NK cells in ITGAL high samples, but ITGAL or FERMT3 expression did not…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsImmune cells in cancer · Bladder and Urothelial Cancer Treatments · Cancer Immunotherapy and Biomarkers